092730.KQ NeoPharm CO., LTD. Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
01:39
Jul 13
Son Soo-hyun Private Banker, Hana Securities Yongsan WM Center 3PRO TV (삼프로TV)
Dalba earnings risk from marketing‑revenue timing gap
Dalba (NeoPharm) faces an accounting-related earnings risk. Amazon Prime Day was pulled earlier, so marketing costs were likely spent in Q2 while revenue may be recognized in Q3, creating a possible Q2 earnings miss. Although the brand is strong and SKU expansion continues, this uncertainty makes the stock risky near‑term. The speaker previously liked it but now recommends avoiding it in favor of APR.
092730.KQ 1ST
MED

About 092730.KQ Analyst Coverage

Buzzberg tracks 092730.KQ (NeoPharm CO., LTD.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Son Soo-hyun.